Squamous cell carcinoma of the lung is linked to smoking and requires early detection and accurate staging for effective treatment. Diagnosis involves imaging and biopsy, with the TNM system used to ...
Lung Squamous cell carcinoma (LSCC) represents the second most common non-small cell lung cancer. Although studies identified adenocarcinoma-like driver mutations in LSCC using next-generation ...
Invasive lung squamous cell carcinoma (LUSC) accounts for approximately one-quarter of all lung cancers, but therapeutic options for LUSC remain limited, primarily due to the absence of well-defined, ...
Invasive lung squamous cell carcinoma (LUSC) accounts for approximately one-quarter of all lung cancers, but therapeutic options for LUSC remain limited, primarily due to the absence of well-defined, ...
Pfizer Inc. (NYSE: PFE) today announced topline results from the Phase 3 SigVie-002 study (previously known as Be6A Lung-01) ...
Safety and efficacy of pembrolizumab plus lenvatinib as first-line therapy in non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials. Real-world outcomes of ...
Pfizer (NYSE:PFE) reported that its late stage lung cancer drug sigvotatug vedotin did not significantly improve overall ...
Pfizer Inc. PFE on Monday reported mixed topline results from its Phase 3 SigVie-002 trial of investigational antibody-drug ...
By Michael Erman June 22 (Reuters) - Pfizer said on Monday that one of the key experimental drugs it picked up in its $43 billion 2023 acquisition of Seagen failed to improve survival when compared to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results